ResMed Inc. (RMD) Insider David Pendarvis Sells 2,804 Shares
ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 2,804 shares of ResMed stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $84.17, for a total value of $236,012.68. Following the sale, the insider now directly owns 97,257 shares in the company, valued at $8,186,121.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
David Pendarvis also recently made the following trade(s):
- On Friday, November 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $82.20, for a total value of $523,120.80.
- On Tuesday, October 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $76.94, for a total value of $489,646.16.
ResMed Inc. (RMD) traded up $0.78 during trading hours on Wednesday, hitting $84.35. 588,400 shares of the stock were exchanged, compared to its average volume of 854,959. ResMed Inc. has a 52 week low of $58.71 and a 52 week high of $87.81. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $11,858.91, a PE ratio of 29.12, a P/E/G ratio of 1.86 and a beta of 0.78.
ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million during the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. ResMed’s quarterly revenue was up 12.5% compared to the same quarter last year. analysts anticipate that ResMed Inc. will post 3 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.66%. The ex-dividend date of this dividend is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is currently 56.68%.
Large investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC bought a new position in ResMed in the 3rd quarter worth approximately $113,000. YorkBridge Wealth Partners LLC raised its position in ResMed by 4.9% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 69 shares during the last quarter. Creative Planning raised its position in ResMed by 97.1% in the 2nd quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after purchasing an additional 823 shares during the last quarter. Toronto Dominion Bank raised its position in ResMed by 12.8% in the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the last quarter. Finally, BB&T Investment Services Inc. bought a new position in ResMed in the 2nd quarter worth approximately $214,000. Institutional investors own 62.02% of the company’s stock.
RMD has been the topic of a number of recent research reports. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Thursday, October 12th. Northland Securities reaffirmed a “sell” rating and set a $55.00 price objective on shares of ResMed in a report on Friday, October 27th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, September 8th. J P Morgan Chase & Co lifted their price objective on ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a report on Monday, October 30th. Finally, Barclays lifted their price objective on ResMed from $65.00 to $68.00 and gave the company an “underweight” rating in a report on Monday, September 25th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. ResMed has a consensus rating of “Hold” and an average price target of $67.57.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.